查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲高度活躍的原料藥市場：分析與預測（2023-2033）
市場調查報告書
商品編碼
1501635

歐洲高度活躍的原料藥市場：分析與預測（2023-2033）

Europe Highly Potent API Market - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 65 Pages | 商品交期: 1-5個工作天內

價格

歐洲高活性 API 市場規模預計將從 2023 年的 59.8 億美元增至 2033 年的 163.3 億美元，預測期內複合年成長率為 10.57%。

推動高度活躍的原料藥市場擴張的主要因素是癌症發生率的上升和原料藥治療應用的擴大。

主要市場統計數據
預測期 2023-2033
2023年評估 59.8億美元
2033年預測 163.3億美元
複合年成長率 10.57%

由於癌症發生率的增加以及 HPAPI 在各個治療領域的應用不斷擴大，歐洲高度活躍的 API 市場正在顯著成長。該地區強大的製藥業得到先進研發設施和嚴格法律規範的支持，促進了市場發展。歐洲主要企業正在大力投資製造能力和聯合夥伴關係，以滿足不斷成長的需求。此外，創新技術和工藝的採用確保了高品質和安全的HPAPI的生產。此外，外包給專門的受託製造廠商（CMO）的趨勢日益明顯，這些組織是處理高活性化合物、確保安全和遵守環境法規以及降低製藥公司營運成本的專家，這正在推動市場發展。

本報告調查了歐洲高度活躍的原料藥市場，包括行業趨勢、技術和專利趨勢、法律制度、市場成長促進和限制、市場規模趨勢和預測，以及主要國家的詳細分析、競爭格局、主要企業簡介等

目錄

執行摘要

第1章 市場

  • 趨勢：當前和未來的影響評估
    • 趨勢 1：高效能 API 密封技術的進步
    • 趨勢2：增加對高效能原料藥生產單位的投資
    • 趨勢3：製藥公司將高效率原料藥的生產外包給CDMO
  • 供應鏈/價值概述
    • 供應鏈及供應鏈風險
    • 價值鏈分析
  • 價格分析
  • 專利申請趨勢（按年份/國家）
  • 監管狀況
  • 全球重大事件的影響分析：COVID-19
  • 市場動態：概述
    • 市場促進因素
    • 市場機會
    • 市場限制因素

第2章 區域

  • 區域概況
  • 歐洲
    • 區域概況
    • 市場成長推進因素
    • 市場問題
    • 法國
    • 德國
    • 英國
    • 西班牙
    • 義大利
    • 其他

第3章市場：競爭基準化分析/公司簡介

  • 下一個前沿
  • 地理評估
    • Almac Group
    • Axplora Group GmbH
    • BASF SE
    • CordenPharma International
    • Helsinn Healthcare SA.
    • ICROM
    • Lonza
    • Merck KGaA
    • Sterling Pharma SolutionsAlmac Group

第4章調查方法

Product Code: BHL2156SS

Introduction to Europe Highly Potent API Market

The Europe highly potent API market is projected to reach $16.33 billion by 2033 from $5.98 billion in 2023, growing at a CAGR of 10.57% during the forecast period 2023-2033. The primary factors propelling the expansion of the highly potent API market are the rising incidence of cancer, which boosts the demand for highly potent APIs, and the broadening range of therapeutic applications for these APIs.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$5.98 Billion
2033 Forecast$16.33 Billion
CAGR10.57%

Market Introduction

The Europe Highly Potent API market is experiencing significant growth, driven by increasing cancer prevalence and the expanding application of HPAPIs in various therapeutic areas. The region's robust pharmaceutical industry, supported by advanced R&D facilities and stringent regulatory frameworks, enhances market development. Key players in Europe are investing heavily in manufacturing capabilities and collaborative partnerships to meet the rising demand. Additionally, the adoption of innovative technologies and processes ensures the production of high-quality, safe HPAPIs. The market is further fueled by the growing outsourcing trend to specialized contract manufacturing organizations (CMOs) with expertise in handling highly potent compounds, ensuring compliance with safety and environmental regulations, and reducing operational costs for pharmaceutical companies.

Market Segmentation:

Segmentation 1: by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How can this report add value to an organization?

Competitive Strategy: The highly potent API market has numerous established players with product and service portfolios. Key players in the Europe highly potent API market analysed and profiled in the study involve established players offering products and services of highly potent API.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, type portfolio, and market penetration.

Some prominent names in the market include:

  • Almac Group
  • Axplora Group GmbH
  • BASF Pharma Solutions
  • CordenPharma International
  • Helsinn Healthcare SA.
  • ICROM
  • Lonza
  • Merck KGaA
  • Sterling Pharma Solutions

Table of Contents

Executive Summary

Scope and Definition

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Trend 1: Advancements in Containment Technologies for Highly Potent APIs
    • 1.1.2 Trend 2: Increasing Investment for Highly Potent API Manufacturing Units
    • 1.1.3 Trend 3: Pharmaceutical Companies Outsourcing Highly Potent APIs Production to CDMOs
  • 1.2 Supply Chain /Value Overview
    • 1.2.1 Supply Chain and Risks within the Supply Chain
    • 1.2.2 Value Chain Analysis
  • 1.3 Pricing Analysis
  • 1.4 Patent Filing Trend (by Year, Country)
  • 1.5 Regulatory Landscape
  • 1.6 Impact Analysis for Key Global Events - COVID-19
  • 1.7 Market Dynamics: Overview
    • 1.7.1 Market Drivers
      • 1.7.1.1 Increasing Incidence of Cancer Leading to Demand in the Adoption of Highly Potent APIs
      • 1.7.1.2 Advancements in Drug Delivery Technologies
      • 1.7.1.3 Expanding Therapeutic Applications of Highly Potent API
    • 1.7.2 Market Opportunities
      • 1.7.2.1 Growing Emphasis on Personalized Medicine
      • 1.7.2.2 Increasing Opportunities for Pharma Companies in Developing Markets
    • 1.7.3 Market Restraints
      • 1.7.3.1 Regulatory Complexity for Highly Potent APIs' Manufacturing
      • 1.7.3.2 High Development and Production Costs

2 Regions

  • 2.1 Regional Summary
  • 2.2 Europe
    • 2.2.1 Regional Overview
    • 2.2.2 Driving Factors for Market Growth
    • 2.2.3 Factors Challenging the Market
    • 2.2.4 France
    • 2.2.5 Germany
    • 2.2.6 U.K.
    • 2.2.7 Spain
    • 2.2.8 Italy
    • 2.2.9 Rest-of-Europe

3 Markets -Competitive Benchmarking & Company Profiles

  • 3.1 Next Frontiers
  • 3.2 Geographic Assessment
    • 3.2.1 Almac Group
      • 3.2.1.1 Overview
      • 3.2.1.2 Key Developments
      • 3.2.1.3 Top Products/Product/Service Portfolio
      • 3.2.1.4 Top Competitors
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Axplora Group GmbH
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products/Product/Service Portfolio
      • 3.2.2.3 Key Developments
      • 3.2.2.4 Top Competitors
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 BASF SE
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products/Product/Service Portfolio
      • 3.2.3.3 Key Developments
      • 3.2.3.4 Top Competitors
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 CordenPharma International
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products/Product/Service Portfolio
      • 3.2.4.3 Key Developments
      • 3.2.4.4 Top Competitors
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Helsinn Healthcare SA.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products/Product/Service Portfolio
      • 3.2.5.3 Key Developments
      • 3.2.5.4 Top Competitors
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 ICROM
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products/Product/Service Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Key Personnel
      • 3.2.6.5 Analyst View
    • 3.2.7 Lonza
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products/Product/Service Portfolio
      • 3.2.7.3 Key Developments
      • 3.2.7.4 Top Competitors
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Merck KGaA
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products/Product/Service Portfolio
      • 3.2.8.3 Key Developments
      • 3.2.8.4 Top Competitors
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Sterling Pharma Solutions
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products/Product/Service Portfolio
      • 3.2.9.3 Key Developments
      • 3.2.9.4 Top Competitors
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Highly Potent API Market (by Region), $Billion, 2022-2033
  • Figure 2: Highly Potent API Market, Recent Developments
  • Figure 3: Highly Potent API Market: Value Chain Analysis
  • Figure 4: Highly Potent API Market: Pricing Analysis
  • Figure 5: Highly Potent API Market, Patent Analysis (by Year), January 2018-December 2023
  • Figure 6: Highly Potent API Market, Patent Analysis (by Country), January 2018-December 2023
  • Figure 7: Regulatory Framework for Highly Potent API
  • Figure 8: Impact Analysis of Market Navigating Factors, 2022-2033
  • Figure 9: Incidence of Cancer (by Region), Million, 2020-2040
  • Figure 10: Europe Highly Potent API Market, $Billion, 2022-2033
  • Figure 11: France Highly Potent API Market, $Billion, 2022-2033
  • Figure 12: Germany Highly Potent API Market, $Billion, 2022-2033
  • Figure 13: U.K. Highly Potent API Market, $Billion, 2022-2033
  • Figure 14: Spain Highly Potent API Market, $Billion, 2022-2033
  • Figure 15: Italy Highly Potent API Market, $Billion, 2022-2033
  • Figure 16: Rest-of-Europe Highly Potent API Market, $Billion, 2022-2033
  • Figure 17: Some of the Key Innovators in the Highly Potent API Landscape
  • Figure 18: Highly Potent API Market: Geographical Assessment
  • Figure 19: Strategic Initiatives, January 2021-December 2023
  • Figure 20: Share of Strategic Initiatives
  • Figure 21: Data Triangulation
  • Figure 22: Top-Down and Bottom-Up Approach
  • Figure 23: Assumptions and Limitations

List of Tables

  • Table 1: Europe Highly Potent API Market Snapshot
  • Table 2: Short-Term and Long-Term Opportunities and Risks (by Region)
  • Table 3: Key Trends, Impact Analysis
  • Table 4: Highly Potent API Market, Key Investment
  • Table 5: Recent Innovations for Manufacturing and Handling of Highly Potent Drugs
  • Table 6: Highly Potent API Market (by Region), $Billion, 2022-2033
  • Table 7: Highly Potent API Market (by Country), $Billion, 2022-2033